NEO-PTC-01

N/A

Report date: 2025/04/20 20:00:03

Base Information

Drug NameNEO-PTC-01
Drug Alias NameNEO-PTC-01BNT-221BNT221
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumNetherlands
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBioNTech US Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBioNTech US Inc
Active IndicationsN/A
Inactive IndicationsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A